Preferred Pharmaceuticals – Recall of losartan

- In March 2019, Preferred Pharmaceuticals announced a voluntary, consumer-level recall of multiple lots of losartan tablets due to the presence of an impurity, N-Methylnitrosobutyric acid (NMBA), found in finished product.

- NMBA is a potential human carcinogen. To date, Preferred Pharmaceuticals has not received any reports of injury or adverse events related to this recall.

    — This recall is being initiated in response to the recall by the manufacturer (Torrent), which included the affected lots that were repackaged by Preferred Pharmaceuticals.
    — Refer to the FDA site for updates regarding angiotensin II receptor blocker recalls.

- The recalled products are listed below:

Product Description	NDC#	Lot# (Expiration Date)
Losartan 50 mg tablets (30 count bottles)	68788-0048-03	C2218C (9/2020); D1318E (10/2020)
Losartan 50 mg tablets (90 count bottles)	68788-0409-09	C2719J (9/2020); E1818B (10/2020)

- Losartan tablets are used for the treatment of hypertension (HTN); to reduce the risk of stroke in patients with HTN and left ventricular hypertrophy; and for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥ 300 mg/g) in patients with type 2 diabetes and a history of HTN.

- Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are on losartan should continue taking their medication, as the risk of harm to a patient's health may be higher if the treatment is stopped immediately without any alternative treatment.

- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled losartan.

- Anyone with an existing inventory of the recalled product should stop use and distribution, and quarantine the product immediately.